

# Grŵp Strategaeth Meddyginiaethau Cymru Gyfan All Wales Medicines Strategy Group



## Final Appraisal Recommendation

Advice No: 1912 – July 2012

**Dihydroartemisinin/piperaquine phosphate (Eurartesim®)  
320 mg/40 mg film-coated tablets**

**Limited submission by Sigma Tau Pharma Ltd UK**

### Recommendation of the All Wales Medicines Strategy Group

**Dihydroartemisinin/piperaquine phosphate (Eurartesim®) is recommended as an option for use within NHS Wales for the treatment of uncomplicated *Plasmodium falciparum* malaria in adults, children and infants 6 months and over and weighing 5 kg or more.**

#### Additional note(s):

- AWMSG is of the opinion that dihydroartemisinin/piperaquine phosphate (Eurartesim®) for the above indication may be appropriate for use within NHS Wales prescribed under specialist recommendation.

In reaching the above recommendation AWMSG has taken account of the appraisal documentation prepared by the AWMSG Secretariat (reference number 1228), which includes the AWMSG Secretariat Assessment Report (ASAR), the Preliminary Appraisal Recommendation (PAR) and the applicant company's response to the PAR, clinical expert opinion (where available), the views of patients/patient carers (where available) and the lay member perspective.

The All Wales Therapeutics and Toxicology Centre (AWTTC) reviewed this appraisal recommendation in August 2022. No new evidence was identified that is likely to significantly affect the current recommendation. Therefore, this recommendation has been transferred to AWMSG's static list of medicine recommendations.

**Statement of use: No part of this recommendation may be reproduced without the whole recommendation being quoted in full and cited as:**

**All Wales Medicines Strategy Group Final Appraisal Recommendation -  
1912: Dihydroartemisinin/piperaquine phosphate (Eurartesim®)  
320 mg/40 mg film-coated tablets. July 2012**